Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. - London | Springer Japan | 2016 - 198 Pages Includes References

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.



ISBN: 978-4-431-55713-5 978-4-431-55714-2 (eBook) = ABL1 achieved apoptosis assay Baccarani BCR BCR gene BCR-ABL BCR-ABL kinase BCR-ABL1 transcript Blood bone marrow bosutinib Branford c-ABL Cancer CCyR cell cycle chromosome chronic myelogenous leukemia chronic myeloid leukemia chronic phase chronic-phase chronic myeloid Clin Oncol clinical CML cells CML patients CML stem cells complete cytogenetic response control gene Cortes dasatinib deep molecular responses detection DNA drug ELN Fig follow-up FoxO3a Gab2 Guilhot F hematologic hematopoietic cells hematopoietic stem cell Hochhaus HSCs Hughes TP imatinib mesylate imatinib-resistant inhibition interferon JAK2 Kantarjian kinase activity kinase domain mutations leukemic major molecular response mice MMR monitoring months NCCN newly diagnosed chronic nilotinib normal HSCs O’Brien OMA oncogene outcome patients with chronic PCR Ph+ phosphorylation pii ponatinib progenitors protein qPCR regulation relapse residual disease response to imatinib risk RT-qPCR Saglio G second-generation TKIs sensitivity SH2 domain survival target TFR TKI therapy TKI treatment treated with imatinib trial tyrosine kinase inhibitors

LCCN: 2015954659

Subjects--Personal Names: --Hematology, Medical / Clinical Medicine, Medical / Hematology, Medical / Oncology / General, Oncology, Medical / Oncology / Leukemia & Lymphoma, Chronic myeloid leukemia -- Molecular aspects, Medicine.